CFRX a great risks/reward ratio! 🧙ContraFect Corp is a cinical-stage biotechnology company which focuses on discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases including those caused by drug-resistant pathogens, particularly treated in hospital settings. The company has developed advanced lysin product candidate, CF-301 for the treatment of Staph aureus bacteremia, including endocarditis. It also emphasizes on addressing drug-resistant infections using product candidates from its lysin and monoclonal antibody platforms that target conserved regions of either bacteria or viruses. The company operates through a single segment being the Development of therapeutic protein and antibody products for life-threatening, drug-resistant infectious diseases.
If you want more trading ideas like this one ,🎯 press a thumb up! 👍 Have a question? Don't be shy to ask! 🤓 Interested to study how to analyze charts, follow me!
Biotechnology
BIIB has incoming Golden Cross, rising past support zone?Hi. In this 1D chart I've marked an impending Golden Cross: the point where a MA 56 is very likely to cross a MA 224 upwards.
With this I've also plotted out a Resistance zone and a Support zone. The price has just entered the Resistance zone but instead of turning back this time the momentum of the Golden Cross should push it past the Resistance zone.
I've also included two example trades. One has its SL placed on the price of the Golden Cross and then given a ratio of two to make a reasonable TP.
The other has its SL placed on the top line of the Support zone and given a ratio of 1.75 to make a more conservative long position and keep the TP within a reasonable price.
Thank you. Please, if you have any thoughts or comments do leave them below and I would gladly discuss or adjust my interpretations and methods with you.
This does not constitute financial advice. Any projected prices, even if explicitly stated, are made with intent to discuss the symbol and potential interpretations. Any trades shown or mentioned are examples and neither recommendations or mandates.
Anti-aging biotech is looking super juicy meow meow style!I don't invest in Pharma, and this isn't Pharma! As I understand it, the company is making implants to help counter the aging process. Very future, very cool!
I think this could be a very good week for this stock!
As always, this is not investment advice!
MVMD — Target of shoddy short hit piece by anonymous SA authorThis is a very similar setup to my earlier EXRO call where an anonymous author calling him/herself “Mariner Research Group” put together a shoddy “short thesis” that was quite frankly garbage. It would not surprise me if this “Night Research Group” is the exact same person. Same quality of work, same hastily put together WordPress website with no contact info other than email and no names of who is behind it. Same terrible track record where none of the previous price targets have been reached. Same low follower count.
From the technical perspective, MVMD is oversold on the hourly and is approaching oversold territory on the daily chart . .95 gap was filled and support was found at the .96 Fibonacci line. If support holds, it will start forming a bullish Double Bottom pattern. There’s also a gap at 1.10 up above. Decent risk/reward but stop loss is not a bad idea, IMO.
Recognized R&D Pioneers in Anti-Inflammatory TherapeuticsThe founding team members at 180 Life Sciences Corp. (NASDAQ: ATNF) are the recognized pioneers of research and development in anti-inflammatory therapeutics.
180 Life Sciences is a clinical-stage biotechnology company that brings together the expertise of world-renowned scientists to develop and test novel treatments for inflammation and is currently working in both preclinical and clinical studies.
finance.yahoo.com
$OI to join S&P SmallCap 600 on March 30Neurocrine Biosciences Inc. (NASD:NBIX) will replace O-I Glass Inc. (NYSE:OI) in the S&P MidCap 400, and O-I Glass will replace HMS Holdings Corp (NASD:HMSY) in the S&P SmallCap 600 effective prior to the opening of trading on Tuesday, March 30.
finance.yahoo.com
$APOP and Quoin Pharmaceuticals Announce Strategic MergerCellect Biotechnology and Quoin Pharmaceuticals Announce Strategic Merger
Up to $25 million of funding at $75 million pre-money valuation to be available to the combined company concurrently with the merger
Cellect shareholders to retain 25% of the combined Company pre-funding
Quoin has secured $25 million in committed equity funding from Altium Capital, a highly regarded institutional healthcare investor.
Quoin has also negotiated an $18.5 million venture loan from a leading U.S. commercial bank.
Completion of the merger is subject to approval of the Cellect and Quoin shareholders and certain other conditions and is expected to close by the end of the second quarter of 2021.
Why $IMMP soared in December case studyFirst time an antigen presenting cell (APC) activator has shown an Overall Survival (OS) benefit in a randomised setting in metastatic breast cancer patients known to be insensitive to immune checkpoint inhibitor therapy
Promising and improving overall trend in OS in total population (based on approx. 60% of events): median survival benefit of +2.7 months from efti plus chemotherapy, compared to chemotherapy plus placebo.
Statistically significant OS benefit in efti group observed in pre-defined patient groups:
+7.1 months survival benefit (median of 21.9 vs. 14.8 months, nearly 50% longer) from efti with chemotherapy for patients under 65 years of age
+9.4 months survival benefit (median of 22.4 vs. 12.9 months, 74% longer) from efti with chemotherapy for patients with a low starting monocyte count
Statistically significant increase in CD8 T cells in patients treated with efti plus chemotherapy, correlated with prolonged OS, indicating pharmacodynamic activity and proof of concept of efti’s mode of action
Collection of OS data ongoing, with final data expected to be reported mid 2021
finance.yahoo.com
$PRQR Announces Positive Results from Clinical Trial of QR-421aProQR Announces Positive Results from Clinical Trial of QR-421a in Usher Syndrome and Plans to Start Pivotal Trials.
QR-421a demonstrated a concordant benefit in multiple measures of vision, including best corrected visual activity (BCVA), static perimetry, and retinal imaging (OCT)
QR-421a observed to be well tolerated with no serious adverse events reported
Two pivotal Phase 2/3 trials are expected to start by the end of 2021
finance.yahoo.com
APOP Cellect Biotechnology Upside PotentialNext time when you see those upside spikes is a chart, that is and extremely bullish sign. Maybe some insider buys!
Cellect Biotechnology Ltd. (NASDAQ: APOP), a developer of innovative technology that enables the functional selection of stem cells, and Quoin Pharmaceuticals Inc. (“Quoin”), a privately held specialty pharmaceutical company, today announced that the Boards of Directors of the two companies have unanimously approved a definitive Merger Agreement. (globenewswire.com)
Market Cap of only 13.644M. This still has room to grow!
If you are interested to test some amazing BUY and SELL INDICATORS which give the signal at the beginning of the candle, not at the end of it, just leave me a message.
$HOTH Announces Positive Data from Animal TestingVoltron Therapeutics, Inc. Announces Positive Data from Animal Testing of Self-Assembling Vaccine in the Fight Against COVID-19
today announced positive data from its second set of preclinical animal testing of its HaloVax™ Self-Assembling Vaccine (SAV) against COVID-19.
finance.yahoo.com
$bntc Skyrocket as Morgan Stanley Takes StakeBenitec Shares Skyrocket as Morgan Stanley Takes Stake
$BNTC shares blasted higher Tuesday after disclosing in a regulatory filing that Morgan Stanley has a 5.2% stake in the genetic drug company.
The stake amounts to 249,174 shares, or about $1.51 million.
Benitec‘s “proprietary platform, called DNA-directed RNA interference, or ddRNAi, combines RNA interference, or RNAi, with gene therapy to create medicines that facilitate sustained silencing of disease-causing genes following a single administration,” the company said.
“The company is developing ddRNAi-based therapeutics for chronic and life-threatening human conditions including Oculopharyngeal Muscular Dystrophy (OPMD), and Chronic Hepatitis B.”
www.thestreet.com
BNTC Benitech Biopharma we bought the dipMorgan Stanley disclosed in an SEC filing that it had increased its stake in the company by around 5.2%!
Don`t worry, it has still upside potential, despite the 130% increase in the Pre-Market.
Market Cap of only 15.37M
This is a 5X stock, Not trading advice as you know! :)
This was a private call from my trading group and one of my top picks for March.
You can check the transcripts here:
www.patreon.com
If you are also interested to test some amazing BUY and SELL INDICATORS that i use, which give the signal at the beginning of the candle, not at the end of it, just leave me a message.
SELB Back In High TrafficSELB is back in the upper area of its high-traffic support/resistance from several times prior. Most recently, it saw this act as support in February. But it wasn't able to sustain the level. Anyway, it's back at this but in this case, the level has acted as a potential resistance (for now). It's gonna be interesting to see what happens next.
Selecta seems to have benefited from a bullish outlook discussed by the company in its last corporate update.
“We are very pleased by the continued progress of our gene therapy program. In collaboration with AskBio, our lead program in methylmalonic acidemia, is on track to enter the clinic in the second quarter of this year, and we expect initial data by the end of the year,” said Carsten Brunn, Ph.D., president, and chief executive officer of Selecta.
“A key objective of 2021 will be to generate human data in our gene therapy programs and to continue to build our extensive pipeline in gene therapies, enzyme therapies–with an expected IND filing by the end of the year in IgA nephropathy–and autoimmune diseases, as we work to deliver on our mission to leverage our pioneering ImmTOR platform to improve the lives of patients and their families.”
Quote Source: Best Penny Stocks On Robinhood To Watch This Week If You Like Biotech
Rubraca® Significantly Improves Progression-Free SurvivalClovis Oncology’s Rubraca® (rucaparib) Significantly Improves Progression-Free Survival versus Chemotherapy in Patients with Later-line Ovarian Cancer Associated with a BRCA Mutation
The ARIEL4 study met its primary endpoint, showing a statistically significant improvement in investigator-assessed progression-free survival (PFS) for Rubraca versus chemotherapy
The safety of Rubraca observed in the ARIEL4 study was highly consistent with both the U.S. and EU product labels.
$IMTX positive clinical data update from Phase 1 trialsImmatics Presents Data Update on Dose Escalation from Ongoing ACTengine® Cell Therapy Programs
·First anti-tumor activity observed in heavily pre-treated solid cancer patients during early phases of dose escalation
·Tumor shrinkage observed in 8 out of 10 patients including one partial response consistent with robust biological activity of infused T cell products
·Treatment-emergent adverse events were transient and manageable
finance.yahoo.com
$ZCMD Zhongchao Renews Contract with China Association of HealthZhongchao Renews Contract with China Association of Health Promotion and Education and GlaxoSmithKline
Extending the Cooperation in Pulmonary Arterial Hypertension
$ZCMD yesterday announced the renewal of its partnership with the China Association for Health Promotion and Education and GlaxoSmithKline (China) Investment Limited to continue the medical education program "Pulmonary Arterial Hypertension Online Course – Connections with Famous Hospitals" ("PAH Project") in 2021.
finance.yahoo.com
$CANF Signs $42.7 Million Out-Licensing Deal with EwopharmaCan-Fite Signs $42.7 Million Out-Licensing Deal with Ewopharma
Swiss Ewopharma to market Piclidenoson and Namodenoson in Central Eastern Europe (CEE)
$2.25 million upfront payment with an additional $40.45 million for regulatory & sales milestones and 17.5% royalties are included
finance.yahoo.com
$RUBY Doubles on Progress in Early-Stage Cancer-Drug TrialRubius Therapeutics Reports Initial Clinical Data from Ongoing Phase 1/2 Trial of RTX-240 in Patients with Advanced Solid Tumors, Demonstrating Single-Agent Activity.
RTX-240 Generated Partial Responses in Metastatic Anal Cancer and Metastatic Uveal Melanoma Patients; No DLTs or Related Grade 3/4 Adverse Events
RTX-240 Promoted Trafficking of NK and T Cells into
Tumor Microenvironment
Initial Clinical Data Provide Evidence of Broad Potential of RED PLATFORM® Across Pipeline of Cancer and Autoimmune Programs
The initial data "demonstrate that RTX-240 has the potential to generate single-agent activity in patients with solid tumors, including a cold tumor such as metastatic uveal melanoma, where other treatments have failed to induce responses in patients," Christina Coughlin, an oncologist and immunologist who is chief medical officer at Rubius Therapeutics, said in a statement.
“The encouraging safety results, including a single event of Grade 1 liver toxicity, and preliminary efficacy data for RTX-240 to date give us the potential to realize the power of immune agonists for the treatment of cancer," Coughlin added.
The ongoing Phase 1/2 clinical trial of RTX-240 in patients with advanced solid tumors resulted in a 54% confirmed partial response rate in reducing the target lesions in a patient with metastatic anal cancer.
The adverse effects of the treatment included fatigue, chills, nausea, decreased appetite and arthralgia, which is pain in a joint.
Rubius is now planning a new Phase 1 study for the second half of 2021 to evaluate the combination of RTX-240 and another therapy.
It's also planning a Phase 2 expansion cohort for first-quarter 2022, according to its statement.
www.thestreet.com
finance.yahoo.com
BIOL Back In The Channel AgainIt's almost exhausting watching BIOL do this every time...jump, fall, jump, fall, all right back to this channel. There's an interim gap to fill from a few weeks back but still many other levels to consider IF it can break back above and out of this channel. I think volume will be an indicator to watch in consideration of whether or not this can happen.
Because dental procedures have resumed to most of their pre-covid levels, many investors are bullish on the future of Biolase. While it is affected by the pandemic, the company is working to build new strategies. This goes hand in hand with its need to continue innovating and receiving new patents. With all of this in mind, is BIOL a penny stock to watch?
Quote Source: 5 Biotech Penny Stocks On Robinhood To Watch In March 2021
SYN Still Trying To Fill The GapThere's still a pretty big gap to fill from a few years ago but again, with a lot of biotech gaining recently, small caps could be back on the menu.
After Maxim Group upgraded SYN from a hold to a buy, shares of the biotech company dramatically increased. In addition to this, Maxim Group analysts gave a price target for SYN of $2.50. This represents a 10% or so gain from where it was before the rating. At the end of Friday, March 12th, SYN stock had shot up by over 29% to $0.92...CEO Steven Shallcross stated that “we are more encouraged than ever by this outlook for the business as we have made important progress during the fourth quarter advancing and demonstrating the significant value of our clinical development programs. With a number of upcoming catalysts later this year, we believe there is potential to continue to deliver significant value for our shareholders.”
Quote Source: 5 Biotech Penny Stocks On Robinhood To Watch In March 2021
$INVO Expands Amended U.S. Commercialization AgreementINVO Bioscience Expands Company-Owned Clinic Opportunity Under Amended U.S. Commercialization Agreement
$INVO today announced an amendment under its exclusive U.S. commercialization agreement with Ferring Pharmaceuticals. The amendment provides for an increase in the number of INVO company-owned clinics initially allowable under the agreement and removes certain geographical restrictions.
The amendment also adjusted the remaining annual 2020 minimum contractual product purchase requirement, whereby Ferring will place a $501,000 order, which will be recognized as revenue by INVO Bioscience in the first quarter of 2021.
